| Prev Close: | 2.24 |
|---|---|
| Open: | 2.32 |
| Bid: | 2.23 x 2000 |
| Ask: | 2.26 x 100 |
| 1y Target Est: | 5.00 |
| Beta: | 1.94 |
| Next Earnings Date: | 10-Jun-13 |
| Day's Range: | 2.24 - 2.32 |
|---|---|
| 52wk Range: | 1.33 - 3.16 |
| Volume: | 13,264 |
| Avg Vol (3m): | 102,121 |
| Market Cap: | 88.36M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.02 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Interesting ENZ Call For January 2014at TheStreet(Mon, May 20)
- Enzo Biochem's Intellectual Property Protection To Attract Investor Attention In 2013at Seeking Alpha(Mon, May 13)
- Enzo and NIH File Patent Application for Therapies, Diagnosis, and Prognosis for Autoimmune DiseasesBusiness Wire(Tue, May 7)
- Could Enzo Biochem's Intellectual Property Lawsuits Be Worth Billions?at Seeking Alpha(Sun, Apr 28)
- ENZO BIOCHEM INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and ExhibitsEDGAR Online(Mon, Apr 22)
- ENZO BIOCHEM INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements aEDGAR Online(Thu, Mar 28)
- The Market Likes Sangamo's Search For An HIV/AIDS Cureat Seeking Alpha(Mon, Mar 25)
- Enzo Investors Have To Be In It For The Long Haulat Seeking Alpha(Wed, Mar 20)
- ENZO BIOCHEM INC FinancialsEDGAR Online Financials(Sat, Mar 16)
- Gain Capital posts quarterly loss, Inter Parfums profits up (Video)at bizjournals.com(Wed, Mar 13)
- ENZO BIOCHEM INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FinanciEDGAR Online(Wed, Mar 13)
- Enzo Biochem Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Mar 13)
- Enzo Biochem Earnings Call scheduled for 8:30 am ET todayCCBN(Wed, Mar 13)
- ENZO BIOCHEM INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Mar 12)
- Enzo Biochem Reports Fiscal Second Quarter ResultsBusiness Wire(Tue, Mar 12)
Press Releases
- Enzo and NIH File Patent Application for Therapies, Diagnosis, and Prognosis for Autoimmune DiseasesBusiness Wire(Tue, May 7)
- Enzo Biochem Reports Fiscal Second Quarter ResultsBusiness Wire(Tue, Mar 12)
- Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.Business Wire(Fri, Mar 8)
Reports
- ENZ: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 24)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(May 24)
- Enzo Biochem Inc (ENZ) Profile and Financials, plus Consulting Industry Trends...Plunkett Research, Ltd.(May 23)